Vaxchora

RSS

cholera vaccine, oral, live

Authorised
This medicine is authorised for use in the European Union.

Overview

Vaxchora is a vaccine to prevent cholera disease in adults and children aged from 2 years. Cholera is a disease that is caught from contaminated food or drink and causes severe diarrhoea.

The vaccine contains a weakened form of the cholera bacterium Vibrio cholerae (serogroup O1).

This EPAR was last updated on 06/10/2023

Authorisation details

Product details
Name
Vaxchora
Agency product number
EMEA/H/C/003876
Active substance
vibrio cholerae, strain cvd 103-hgr, live
International non-proprietary name (INN) or common name
cholera vaccine, oral, live
Therapeutic area (MeSH)
Cholera
Anatomical therapeutic chemical (ATC) code
J07AE02
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
Bavarian Nordic A/S
Revision
7
Date of issue of marketing authorisation valid throughout the European Union
01/04/2020
Contact address

Bavarian Nordic A/S
Philip Heymans Alle 3
11
DK-2900 Hellerup
Denmark
 

Product information

22/09/2022 Vaxchora - EMEA/H/C/003876 - T/0021

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Vaccines

Therapeutic indication

Vaxchora is indicated for active immunisation against disease caused by Vibrio cholerae serogroup O1 in adults and children aged 2 years and older.

This vaccine should be used in accordance with official recommendations.

Assessment history

Related content

How useful was this page?

Add your rating